Clinical trial · Interventional
Sorafenib in BAC or Never-Smokers With Lung Adenocarcinoma
A Phase II Trial of Sorafenib in BAC or Never-Smokers With Any Lung Adenocarcinoma
NCT00456716CI-TRIAL-00003235completedPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Open label study of sorafenib
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Lung Cancer | Malignant Lung Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| sorafenib | Drug | Sorafenib | ALIAS |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (3)
- measure
- Response rate
- timeFrame
- January 2009
- measure
- One-year survival
- timeFrame
- January 2009
- measure
- Median survival
- timeFrame
- January 2009
Secondary outcomes (2)
- measure
- Median progression-free survival
- timeFrame
- January 2009
- measure
- Toxicities
- timeFrame
- January 2009
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Age \> 18 * Life expectancy \> 12 weeks * Biopsy-proven BAC or adenocarcinoma * Willing to provide smoking status * Selected IIIB or stage IV cancer that is incompletely resected or unresectable Exclusion Criteria: * O2 saturation \< 88% on room air * Pregnant or nursing women * Surgery or radiation therapy within 4 weeks of starting study * Major heart condition within 6 months of starting therapy * Certain concomitant medications prohibited
References
Publications (0)
Data not yet available
No reference posted for this study.